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Abstract
Solid organ transplant recipients have elevated cancer risks, due in part to pharmacologic 
immunosuppression. However, little is known about risks for hematologic malignancies of 
myeloid origin. We linked the US Scientific Registry of Transplant Recipients with 15 population-
based cancer registries to ascertain cancer occurrence among 207,859 solid organ transplants 
(1987–2009). Solid organ transplant recipients had significantly elevated risk for myeloid 
neoplasms, with standardized incidence ratios (SIRs) of 4.6 (95% confidence interval 3.8–5.6; 
N=101) for myelodysplastic syndromes (MDS), 2.7 (2.2–3.2; N=125) for acute myeloid leukemia 
(AML), 2.3 (1.6–3.2; N=36) for chronic myeloid leukemia, and 7.2 (5.4–9.3; N=57) for 
polycythemia vera. SIRs were highest among younger individuals and varied by time since 
transplantation and organ type (Poisson regression P<0.05 for all comparisons). Azathioprine for 
initial maintenance immunosuppression increased risk for MDS (P=0.0002) and AML (2–5 years 
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after transplantation, P=0.0163). Overall survival following AML/MDS among transplant 
recipients was inferior to that of similar patients reported to US cancer registries (log-rank 
P<0.0001). Our novel finding of increased risks for specific myeloid neoplasms after solid organ 
transplantation supports a role for immune dysfunction in myeloid neoplasm etiology. The 
increased risks and inferior survival should heighten clinician awareness of myeloid neoplasms 
during follow-up of transplant recipients.
INTRODUCTION
In the United States (US), nearly 30 000 patients annually undergo solid organ 
transplantation.1 Clinical advances have led to substantial improvements in survival 
following transplantation, increasing the public health and clinical importance of 
understanding the long-term health effects of solid organ transplantation. The elevated 
cancer risks experienced by transplant recipients, largely due to pharmacologic 
immunosuppression to prevent graft rejection, are a key cause of morbidity and mortality 
following transplantation.1–3
Post-transplantation lymphoproliferative disorders (PTLDs) are among the most common 
serious complications of transplantation,1 but much less is known about the risks for 
hematologic malignancies of myeloid origin. Increased risks have been reported after solid 
organ transplantation for all myeloid neoplasms combined4, 5 and for acute myeloid 
leukemia (AML).6, 7 However, myeloid neoplasms comprise a range of diseases – including 
AML, myelodysplastic syndrome (MDS, which may progress to AML), chronic myeloid 
leukemia (CML), and other rarer entities such as polycythemia vera.8 Survival following a 
myeloid neoplasm diagnosis is generally poor, with estimated 5-year relative survival of 
22% for AML, 41% for MDS, and 68% for CML in the US.9 Exposure to ionizing radiation 
and cytotoxic chemotherapy are established risk factors for certain myeloid neoplasms,10 but 
otherwise the causes of these malignancies remain unclear.8, 11 Evidence increasingly 
supports a role for immune dysfunction in the development of myeloid neoplasms, with 
elevated risks observed for individuals with a history of certain infections and autoimmune 
disease12–15 or HIV/AIDS.16, 17
We therefore conducted the first comprehensive investigation of the spectrum of risks for 
specific myeloid neoplasms among 207 859 solid organ transplants occurring in the US 
during 1987–2009 in the Transplant Cancer Match Study.2
METHODS
Transplant Cancer Match Study
The Transplant Cancer Match Study (www.transplantmatch.cancer.gov)2 provides 
comprehensive, systematic cancer ascertainment for solid organ transplant recipients by 
linking data from the Scientific Registry of Transplant Recipients (SRTR) with population-
based cancer registries. The SRTR includes detailed information on all US solid organ 
transplants since 1987. Structured data are obtained regularly from transplant centers, 
including information on recipients (e.g., demographics, medical history, indication for 
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transplant [Supplemental Table]), type of organ transplanted, and medications used for 
induction and baseline maintenance of immunosuppression to prevent graft rejection.
During 2008–2012, serial record linkages were completed between the SRTR and 15 
population-based cancer registries: California (years of coverage: 1988–2008), Colorado 
(1988–2009), Connecticut (1973–2009), Florida (1981–2009), Georgia (1995–2008), 
Hawaii (1973–2007), Illinois (1986–2007), Iowa (1973–2009), Michigan (1985–2009), 
North Carolina (1990–2007), New Jersey (1979–2006), New York (1976–2007), Seattle/
Puget-Washington (1974–2008), Texas (1995–2006), and Utah (1973–2008). Transplant 
recipients residing in these registry areas during the specified time periods were eligible for 
this analysis (46% of the US transplant population). We further excluded transplant 
recipients with unknown race/ethnicity (N=1421) or history of HIV (N=238). The study was 
approved by human subjects research review committees at the National Cancer Institute 
and, as required, participating cancer registries.
Myeloid Neoplasm Ascertainment
Incident diagnoses of myeloid neoplasms were identified through the cancer registries using 
International Classification of Diseases for Oncology, 3rd Edition morphology codes,18 
grouped according to the World Health Organization8 classification into AML (9840, 9861, 
9866–9867, 9870–9874, 9891, 9895–9897, 9910, 9920, 9930–9931), MDS (9980–9989), 
CML (9863, 9875–9876), chronic myelomonocytic leukemia (CMML; 9945–9946), 
polycythemia vera (9950), and other chronic myeloproliferative disorders (9960–9964, 
9975; combined due to small numbers of observed cases). CMML, MDS, polycythemia 
vera, and other chronic myeloproliferative disorders only became reportable to cancer 
registries in 2001 and, thus, were not ascertained prior to 2001.
Statistical Analysis
For each transplant, follow-up began on the date of transplantation, start of cancer registry 
coverage, or (for evaluation of CMML, MDS, polycythemia vera, and other chronic 
myeloproliferative diseases) January 1, 2001, whichever came last. Follow-up ended at the 
earliest of: myeloid neoplasm diagnosis, graft failure, re-transplantation, death, loss to 
follow-up, or end of cancer registry coverage. Follow-up time ended at graft failure or re-
transplantation due to substantial changes in clinical status (e.g., immunosuppression 
medication use) associated with these events.
To quantify risk of myeloid neoplasms after solid organ transplantation in comparison with 
the general population, we used standardized incidence ratios (SIRs). Expected numbers of 
cases were calculated by applying myeloid neoplasm incidence in the cancer registry areas 
to the person-time at risk of the transplant recipients, stratifying on age (5-year groups), sex, 
race/ethnicity, calendar year, and registry. Exact 95% confidence intervals (CIs) about the 
SIR were computed based on the Poisson distribution. We compared myeloid neoplasm 
SIRs for recipient subgroups (e.g., defined by age at transplantation or organ type) using a 
Wald test (Phomogeneity) derived from multivariate Poisson regression models that included 
terms for age at transplantation, sex, race, transplanted organ, and year of transplantation.
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We conducted a sensitivity analysis restricted to those transplants performed during years 
when cancer registries captured the cancers of interest (i.e., transplants for which follow-up 
began at the date of transplantation). For AML and CML, this analysis included transplants 
occurring after the start of cancer registry coverage (N=202 626 transplants). For CMML, 
MDS, polycythemia vera, and other chronic myeloproliferative disorders, this analysis 
included transplants occurring in 2001 or later (N=105 130 transplants). Because the 
occurrence of a previous cancer may alter risk of subsequent myeloid neoplasms, we 
conducted a second sensitivity analysis restricting the cohort to individuals with no history 
of cancer prior to transplantation and censoring people when they developed any cancer (for 
AML and CML: N=194 355 transplants; for CMML, MDS, polycythemia vera, and other 
chronic myeloproliferative disorders: N=105 130). Results from these sensitivity analyses 
were similar to the main results and, thus, are not presented.
To understand the clinical impact of myeloid neoplasms in solid organ transplant recipients, 
we conducted two types of analyses. First, we estimated the relative risk (RR) of mortality 
from any cause associated with myeloid neoplasm development using hazard ratios (HRs) 
and 95% CIs derived from multivariate Cox regression models. Models used time since 
transplantation as the time scale and were adjusted for age at transplantation, sex, race, 
transplanted organ, and year of transplantation, with a time-dependent covariate indicating 
myeloid neoplasm diagnosis. Second, we constructed Kaplan-Meier curves for overall 
survival (i.e., time before death due to any cause) after myeloid neoplasm diagnosis, 
comparing transplant recipients to individuals with the same diagnoses reported to 17 SEER 
cancer registries.9 Because demographic factors are important determinants of overall 
survival, we individually-matched 10 SEER cases (selected randomly) to each case from the 
transplant population by age and calendar year of myeloid neoplasm diagnosis (±5 years), 
sex, and race/ethnicity. Overall survival was then compared between the two patient 
populations using the log-rank test.
RESULTS
Among 207 859 solid organ transplants occurring during 1987–2009 (950 464 person-years 
of follow-up), kidney was the most frequently transplanted organ (58%), followed by liver 
(22%), heart (10%), lung (4%), and other or multiple organs (6%, Table 1). The majority of 
recipients were male (61%) and non-Hispanic white (62%), and most transplants occurred at 
ages 35–64 years (67%). Recipient characteristics varied by type of transplanted organ. In 
particular, the proportion of males ranged from 52% for lung recipients to 75% for heart 
recipients, and the proportion of individuals aged ≥50 years at transplantation ranged from 
21% for recipients of other/multiple organs to 59% for lung recipients.
Compared with the general population, solid organ transplant recipients had significantly 
and substantially elevated risks for myeloid neoplasms, with risks (SIRs) increased 2.7-fold 
(95%CI 2.2–3.2) for AML, 4.6-fold (3.8–5.6) for MDS, 2.3-fold (1.6–3.2) for CML, and 
7.2-fold (5.4–9.3) for polycythemia vera (Table 2). Risks were non-significantly elevated 
2.1-fold (0.8–4.6) for CMML (N=6) and 1.8-fold (1.0–2.9) for other chronic 
myeloproliferative disorders (N=16), but the small numbers of observed cases for these 
entities precluded further analysis.
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Incidence of AML and MDS increased with increasing age at transplantation, reaching 32.2 
and 25.7 cases/100 000 person-years, respectively, for individuals aged ≥65 years at 
transplantation (Figure 1). In contrast, incidence of CML was approximately 5 cases/100 
000 person-years for ages 35–49, 50–64, and ≥65 years, whereas incidence of polycythemia 
vera was approximately 12 cases/100 000 person-years for ages 20–34, 35–49, and ≥65 
years but only 5 cases/100 000 person-years for ages 50–64. Unlike the incidence patterns, 
SIRs for all myeloid neoplasms (reflecting risk relative to the general population) were 
highest in young recipients and decreased monotonically with increasing age, with the 
exception of polycythemia vera.
For AML and polycythemia vera, SIRs also varied significantly by time since 
transplantation (Figure 2). Risks for AML were increased 2.0-fold during the first year 
following transplantation and peaked at 4.6-fold during 1–1.9 years following 
transplantation, with declining risk thereafter (Phomogeneity=0.0456). In contrast, 
polycythemia vera risk was increased 22.0-fold during the first year following 
transplantation, with SIRs dropping precipitously thereafter, yet remaining significantly 
increased 2.9–6.7-fold (Phomogeneity=0.0003). For MDS, risks appeared to decline 
consistently during the first five years following transplantation and increase again 
thereafter, although these changes were not statistically significant (Phomogeneity=0.5170). 
For CML, risk did not vary by time since transplantation (Phomogeneity=0.8049).
In analyses by type of organ transplanted, risk patterns differed for specific myeloid 
neoplasms (Table 2). For MDS, risks were strikingly high among lung recipients (SIR=14.3) 
and recipients of other/multiple organs (SIR=14.0) but substantially lower, albeit still 
significantly elevated compared with the general population, among heart (SIR=4.5), liver 
(SIR=4.4) and kidney (SIR=3.8) recipients (Phomogeneity=0.0001). Risks for AML also were 
highest among lung recipients (SIR=6.5) but were lowest for recipients of other/multiple 
organs (SIR=1.4; Phomogeneity=0.0126). In contrast, risks for polycythemia vera were 9.0-
fold increased among kidney recipients and 21.7-fold increased among recipients of other/
multiple organs, although these differences in risk by organ type were not significant 
(Phomogeneity=0.1580); the strikingly elevated risk for polycythemia vera in the first year 
following transplantation also was evident across organ type (data not shown). Risks for 
CML did not differ significantly by organ type (Phomogeneity=0.9997).
To further understand differences in myeloid neoplasm risk by the type of organ 
transplanted, we explored risks according to receipt of immunosuppressive medications to 
prevent graft rejection and indication for transplantation. Individuals who received 
azathioprine for initial maintenance of immunosuppression had significantly higher risk for 
MDS (SIR=8.4 vs. 3.5, P=0.0002) and for AML occurring 2–5 years after transplantation 
(SIR=6.6 vs. 1.7, P=0.0163; with no association for AML occurring <2 or >5 years after 
transplantation), whereas no association was observed for CML or polycythemia vera. 
Inclusion of azathioprine in the multivariate Poisson regression models for AML and MDS 
reduced the heterogeneity in risks observed by organ type. No other therapies for induction 
of immunosuppression at the time of transplantation (monoclonal antibodies, polyclonal 
antibodies, alemtuzumab, or interleukin-2 receptor antagonists) or for initial maintenance of 
immunosuppression (cyclosporine, tacrolimus, mycophenolate mofetil, mTOR inhibitors, 
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steroids) were associated with myeloid neoplasm risk (data not shown). We also did not 
observe significantly increased risks of myeloid neoplasms associated with broadly defined 
indications for transplantation (data not shown).
Within the cohort of transplant recipients, risk of death was significantly increased 14.4-fold 
(95%CI 11.8–17.6) following the diagnosis of AML, 6.8-fold (5.2–8.7) following MDS, and 
2.4-fold (1.3–4.4) following CML, but not significantly increased following the diagnosis of 
polycythemia vera (RR=1.2, 95%CI 0.6–2.4). Compared to patients reported to SEER 
cancer registries, overall survival was consistently inferior among transplant patients with 
AML (median survival: transplant patients=0.31 years, SEER patients=0.83 years; log-rank 
P<0.0001) and MDS (median survival: transplant patients=1.07 years, SEER patients=2.90 
years; P<0.0001) (Figure 3). In contrast, overall survival following CML and polycythemia 
vera was lower, but not significantly, in transplant patients compared to patients reported to 
SEER cancer registries (P=0.5464 and 0.2105, respectively).
DISCUSSION
By combining national data on solid organ transplantation with systematic cancer 
ascertainment from population-based registries, we provide the first comprehensive study 
demonstrating that transplant recipients have significantly elevated risk for a range of 
myeloid neoplasms. Although these malignancies are relatively rare, the increased risks as 
well as the inferior survival following diagnosis, particularly for AML and MDS, should 
heighten the clinical awareness of myeloid neoplasms during long-term follow-up of solid 
organ transplant recipients.
Our results support a role for immune dysfunction in myeloid neoplasm etiology, consistent 
with the observations of increased myeloid neoplasm risk among individuals with HIV/
AIDS16, 17 or a history of autoimmune disease and infections.12–15 The persistently elevated 
risks for myeloid neoplasms following transplantation varied by type of organ transplanted 
and time since transplantation, with no clear association with specific indications for 
transplantation. Our findings contrast with the U-shaped pattern of risk by time since 
transplantation for NHL,19, 20 for which early-onset disease risks are attributed to Epstein-
Barr virus infection and receipt of T-cell depleting polyclonal antibodies, and later-onset 
disease risks are attributed to longer-term immunosuppression.19, 21, 22
AML and MDS were the most commonly occurring myeloid neoplasms in solid organ 
transplant recipients. The higher risks we observed for lung recipients compared with 
recipients of other organs were attributable in part to the increased use of azathioprine, 
which was associated with increased risk of AML and MDS. Our findings are consistent 
with a previous study of AML among solid organ transplant recipients6 and confirm 
previous reports of increased AML/MDS risk associated with use of azathioprine or other 
antimetabolites.6, 23–28 In current clinical practice in the US, azathioprine is used 
infrequently in solid organ transplant recipients, having been largely replaced by 
mycophenolate mofetil.29 Although the lack of association between myeloid neoplasm risk 
and mycophenolate mofetil or any of the other immunosuppressive drugs we evaluated is 
reassuring, our results should be interpreted cautiously in light of the potential for 
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incomplete ascertainment of medication use, lack of information on long-term use, and our 
inability to evaluate drug doses.30 Clinical awareness of myeloid neoplasm risk after solid 
organ transplantation is particularly relevant for MDS/AML due to the improved outcomes 
for patients treated for MDS before progression to AML.
We also observed elevated risks for CML and polycythemia vera. CML is a relatively rare 
malignancy with a largely unknown etiology. The elevated risks observed in our study were 
consistent with those reported previously in the Transplant Cancer Match study,2 as well as 
another study.5 Albeit based on small numbers of cases, we did not observe significant 
variation in CML risk by recipient subgroup, unlike the other myeloid neoplasms. Our 
finding of elevated risks for polycythemia vera among solid organ transplant recipients, 
particularly in the first year following transplantation, has not been reported in the literature. 
This association may be spurious, particularly the strikingly elevated risks in the first year 
following transplantation, for example resulting from misdiagnosis among kidney recipients 
with a history of erythropoietin use31 or incidental diagnosis of previously undetected 
disease, particularly in liver recipients with Budd-Chiari syndrome.32 However, risks of 
polycythemia vera remained significantly elevated for the duration of post-transplantation 
follow-up in this study, supporting a causal role for transplantation in polycythemia vera 
development.
Further research is warranted to explore the biological mechanisms that may contribute to 
the development of myeloid neoplasms following solid organ transplantation. 
Pharmacologic immunosuppression to prevent graft rejection may result in loss of critical 
immunosurveillance function, as described for CML.33 Alternatively, a role for immune 
stimulation in AML etiology is supported by a recent report of elevated serum kappa and 
lambda immunoglobulin free light chains (FLCs) prior to the development of AML.34 That 
observation is particularly intriguing in light of similar observations for lymphoma risk after 
solid organ transplantation35 or HIV/AIDS.36 Further research also is warranted to clarify 
the importance of direct cytotoxicity versus immunosuppression intensity or duration of 
certain immunosuppressive agents in myeloid neoplasm etiology.
The incidence of most myeloid neoplasms increased with increasing age. However, the SIR 
for each specific myeloid neoplasm type was significantly higher among younger versus 
older individuals at transplantation, and the median age at diagnosis among transplant 
recipients compared with SEER population-based cases ranged from 17 years younger for 
MDS to 5 years younger for CML. This risk pattern may result from intrinsic susceptibility 
of young individuals to the direct or indirect carcinogenic effects of immunosuppressive 
medications. Alternatively, transplantation may have a larger relative effect in younger 
individuals, who have had less time to accumulate carcinogenic exposures that may lead to 
myeloid neoplasm development.
We present the first large-scale analysis demonstrating that overall survival in transplant 
recipients was significantly inferior for AML and MDS compared with patients diagnosed 
with these malignancies reported to SEER cancer registries. Optimal treatment approaches 
for myeloid neoplasms following transplantation are not known, although normal kidney 
and liver function are required for a number of standard chemotherapeutic regimens. 
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Unfortunately, data on myeloid neoplasm treatments, cytogenetic abnormalities, and 
comorbidities were not available for transplant recipients, and, thus, we could not determine 
whether the observed differences in survival may be explained by differences in these 
factors. Additionally, we lacked detailed data on cause of death, and some deaths in the 
transplant cohort may have been due to transplant-related disease.
The linkage of two major population-based data sources enabled us to conduct the first 
assessment of risk for the spectrum of myeloid neoplasms following solid organ 
transplantation. The population-based nature of the data eliminated the biases associated 
with previous clinical series, whereas the large sample size facilitated investigation of less 
common myeloid neoplasms as well as estimation of risks among patient subgroups. 
However, several limitations of our study should be considered in the interpretation of our 
results. Because cancer diagnoses were ascertained through central registries, standardized 
pathology review was not feasible. Although diagnostic criteria for specific myeloid 
neoplasms has changed over time,8 the impact of these changes on our results was 
minimized by comparing myeloid neoplasm incidence in solid organ transplant recipients to 
that in the general population, which was presumably affected by similar changes. Risks 
may have been underestimated because cancers diagnosed in patients who had migrated out 
of the cancer registry areas were not ascertained, although analyses of migration of the 
transplant population suggest that this affects only a small number of individuals.2 Finally, 
despite the large sample size, our statistical power for evaluating risks in certain patient 
subgroups remained limited.
In summary, we observed significantly elevated risks for AML, MDS, CML, and 
polycythemia vera after solid organ transplantation. Diagnoses of AML, MDS, and CML 
were associated with an increased risk of death within the transplant cohort, and overall 
survival following AML and MDS in transplant recipients was significantly inferior when 
compared with patients with the same diagnoses reported to SEER cancer registries. Our 
findings call for an increased awareness of myeloid neoplasms in the risk/benefit assessment 
for solid organ transplantation and during long-term follow-up of solid organ transplant 
recipients. Additionally, further research is needed to elucidate the role of immune 
dysfunction in myeloid neoplasm etiology and to identify optimal treatments for myeloid 
neoplasms in immunosuppressed individuals.
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Figure 1. Incidence rates (per 100 000 person-years) and standardized incidence ratios* for 
specific myeloid neoplasms by age at transplantation among 207 859 solid organ transplants in 
the United States, 1987–2009
Abbreviations: confidence interval (CI), incidence rate (IR), standardized incidence ratio 
(SIR). SIRs are presented for 0–19, 20–34, 35–49, 50–64, and 65+ years, with estimates 
centered over these intervals.
* IRs and SIRs are not presented when <3 cases were observed due to imprecise estimates.
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Figure 2. Standardized incidence ratios* for specific myeloid neoplasms by time since 
transplantation among 207 859 solid organ transplants in the United States, 1987–2009
Abbreviations: confidence interval (CI), standardized incidence ratio (SIR). SIRs are 
presented for <1, 1–1.9, 2–2.9, 3–3.9, 4–4.9, 5–6.9, 7–8.9, and 9+ years, with estimates 
centered over these intervals.
* SIRs are not presented when <3 cases were observed due to imprecise estimates.
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Figure 3. Overall survival following myeloid neoplasm diagnosis among 207 859 solid organ 
transplants in the United States, 1987–2009, compared with matched* patients reported to the 
SEER Program
Abbreviations: Surveillance, Epidemiology, and End Results (SEER), Scientific Registry of 
Transplant Recipients (SRTR).
* A sample of cases of each myeloid neoplasm type was selected from SEER, individually-
matching 10 SEER cases per transplant case by age and calendar year of myeloid neoplasm 
diagnosis (±5 years), sex, and race.
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